Akouos to Present at Cowen 42nd Annual Heath Care Conference

Rhea-AI Summary

Akouos (NASDAQ: AKUS), a precision genetic medicine company, announced that its CEO, Manny Simons, Ph.D., will participate in a panel discussion on Auditory and Ophthalmology at the Cowen 42^nd Annual Health Care Conference on March 7 at 2:10 p.m. EST. The event will be streamed live on the company's website, with replays available for 30 days. Akouos focuses on gene therapies aimed at restoring hearing for those with disabling hearing loss, utilizing a proprietary adeno-associated viral (AAV) vector library.

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that Manny Simons, Ph.D., M.B.A., co-founder, president, and chief executive officer of Akouos, will participate in a panel discussion titled Auditory and Ophthalmology at the Cowen 42^nd Annual Health Care Conference on Monday, March 7 at 2:10 p.m. EST.

A live webcast of the event will be accessible through the investors section of www.akouos.com. To access the webcast, please go to the Akouos website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. Archived replays will be available on the Akouos website for 30 days following the event.

About Akouos

Akouos is a precision genetic medicine company dedicated to developing gene therapies with the potential to restore, improve, and preserve high-acuity physiologic hearing for individuals living with disabling hearing loss worldwide. Leveraging its precision genetic medicine platform that incorporates a proprietary adeno-associated viral (AAV) vector library and a novel delivery approach, Akouos is focused on developing precision therapies for forms of sensorineural hearing loss. Headquartered in Boston, Akouos was founded in 2016 by leaders in the fields of neurotology, genetics, inner ear drug delivery, and AAV gene therapy.

Contacts

Media:
Katie Engleman, 1AB
katie@1abmedia.com

Investors:
Courtney Turiano, Stern Investor Relations
Courtney.Turiano@sternir.com

FAQ

When will Akouos participate in the Cowen 42nd Annual Health Care Conference?

Akouos will participate on March 7, 2022, at 2:10 p.m. EST.

Who will represent Akouos at the Cowen Conference?

Manny Simons, Ph.D., the CEO of Akouos, will represent the company.

Where can I watch the Akouos panel discussion?

The panel discussion will be available via a live webcast on the Akouos website.

How long will the Akouos webcast be available for replay?

The archived replay of the webcast will be available for 30 days after the event.

What is the focus of Akouos as a company?

Akouos focuses on developing gene therapies to restore and improve hearing for individuals with disabling hearing loss.